` ASMB (Assembly Biosciences Inc) vs S&P 500 Comparison - Alpha Spread

ASMB
vs
S&P 500

Over the past 12 months, ASMB has outperformed S&P 500, delivering a return of 10% compared to the S&P 500's 9% growth.

Stocks Performance
ASMB vs S&P 500

Loading
ASMB
S&P 500
Add Stock
www.alphaspread.com

Performance Gap
ASMB vs S&P 500

Loading
ASMB
S&P 500
Difference
www.alphaspread.com

Performance By Year
ASMB vs S&P 500

Loading
ASMB
S&P 500
Add Stock

Competitors Performance
Assembly Biosciences Inc vs Peers

S&P 500
ASMB
ABBV
AMGN
GILD
VRTX
Add Stock

Assembly Biosciences Inc
Glance View

Market Cap
130.6m USD
Industry
Biotechnology

Assembly Biosciences, Inc. is a biotechnology company, which engages in the development of products for infectious diseases, such as chronic hepatitis B virus and illnesses associated with a dysbiotic microbiome. The company is headquartered in South San Francisco, California and currently employs 102 full-time employees. The company went IPO on 2010-12-17. The firm is focused on discovery and development of therapeutics targeting hepatitis B virus (HBV) and other viral diseases. The Company’s inhibitor product candidates include Vebicorvir (VBR), ABI-H3733, and ABI-4334. Vebicorvir (VBR) is its lead core inhibitor product candidate, which is licensed from Indiana University. VBR is developed for the treatment of the treatment of patients with chronic HBV infection. ABI-H3733 (3733) for chronic HBV infection in the People’s Republic of China, Hong Kong, Taiwan and Macau (the Territory). The firm is conducting Phase I study of 3733. The Company’s research and development programs pursue multiple drug candidates that inhibit the HBV replication cycle and block the generation of covalently closed circular DNA (cccDNA), to discover and develop finite and curative therapies for patients with HBV.

ASMB Intrinsic Value
12.6 USD
Overvaluation 27%
Intrinsic Value
Price
Back to Top